Lexeo Therapeutics, Inc. announced a private placement financing that aims to raise approximately $80 million through the sale of over 20 million shares of its common stock and pre-funded warrants.

Private placement securities continue to offer insurers attractive opportunities to enhance portfolio income, according to a recent Conning report. Conning’s latest Viewpoint commentary, “Private ...

NEW YORK and AMSTERDAM, July 01, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (ATAI) (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental ...

Funding expected to provide cash runway into 2026 98% of investment in private placement from Pre-IPO and/or IPO investors Data update from OST-HER2 Phase 2b clinical trial in recurrent, resected ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX) (“Quince” or the “Company”), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...

Atai Life Sciences announced a financing deal to raise approximately $50 million by selling 18,264,840 ordinary shares and pre-funded warrants to purchase an additional 4,566,210 shares. The funds ...

Just as with private placements of equity, issuing bonds privately requires careful attention to federal law. Bonds are usually classified as "securities," triggering various regulatory requirements.

– Aggregate net proceeds expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease – – Pro forma cash ...

The landscape of retirement planning may soon change profoundly. With the recent signing of an executive order aimed at allowing 401(k) plans to include alternative investments such as private equity, ...